Direct effects of statins on cells primarily involved in atherosclerosis

被引:39
作者
Chen, H [1 ]
Ikeda, U [1 ]
Shimpo, M [1 ]
Shimada, K [1 ]
机构
[1] Jichi Med Sch, Dept Cardiol, Minami Kawachi, Tochigi, Japan
关键词
statins; atherosclerosis; macrophages; endothelial cells; vascular smooth muscle cells;
D O I
10.1291/hypres.23.187
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Statins are lipid-lowering agents which act by inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, This enzyme is responsible for the conversion of HMG-CoA to mevalonate. Products of mevalonate metabolism are critical for several cellular processes of eukaryotic cells, and inhibition of the mevalonate pathway by statins has pleiotropic effects, It has been reported that statins inhibit the migration and proliferation df vascular smooth cells (VSMCs) and macrophages, decrease interleukin-6 and inducible nitric oxide synthase expression in VSMCs, improve endothelial function and up-regulate endothelial nitric oxide synthase expression. The above effects of statins are independent of plasma cholesterol levels, and are completely blocked by exogenous mevalonate and some isoprenoids. These findings suggest that, in addition to their effects on plasma lipids, statins exert direct antiatherosclerotic effects on the cells primarily involved in atherosclerosis.
引用
收藏
页码:187 / 192
页数:6
相关论文
共 60 条
  • [1] INTERLEUKIN-6 IN BIOLOGY AND MEDICINE
    AKIRA, S
    TAGA, T
    KISHIMOTO, T
    [J]. ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 : 1 - 78
  • [2] AMINOU PN, 1997, BIOCHIM BIOPHYS ACTA, V1345, P259
  • [3] CHANGES INDUCED BY PRAVASTATIN TREATMENT ON HEMOSTATIC AND FIBRINOLYTIC PATTERNS IN PATIENTS WITH TYPE IIB HYPERLIPOPROTEINEMIA
    AVELLONE, G
    DIGARBO, V
    CORDOVA, R
    RANELI, G
    DESIMONE, R
    BOMPIANI, G
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1994, 55 (11): : 1335 - 1344
  • [4] Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells
    Baetta, R
    Donetti, E
    Comparato, C
    Calore, M
    Rossi, A
    Teruzzi, C
    Paoletti, R
    Fumagalli, R
    Soma, MR
    [J]. PHARMACOLOGICAL RESEARCH, 1997, 36 (02) : 115 - 121
  • [5] Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy
    Ballantyne, CM
    Herd, JA
    Ferlic, LL
    Dunn, JK
    Farmer, JA
    Jones, PH
    Schein, JR
    Gotto, AM
    [J]. CIRCULATION, 1999, 99 (06) : 736 - 743
  • [6] Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery
    Bandoh, T
    Mitani, H
    Niihashi, M
    Kusumi, Y
    Ishikawa, J
    Kimura, M
    Totsuka, T
    Sakurai, I
    Hayashi, S
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 315 (01) : 37 - 42
  • [7] HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
    Bellosta, S
    Via, D
    Canavesi, M
    Pfister, P
    Fumagalli, R
    Paoletti, R
    Bernini, F
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (11) : 1671 - 1678
  • [8] REQUIREMENT FOR MEVALONATE IN ACETYLATED LDL INDUCTION OF CHOLESTEROL ESTERIFICATION IN MACROPHAGES
    BERNINI, F
    DIDONI, G
    BONFADINI, G
    BELLOSTA, S
    FUMAGALLI, R
    [J]. ATHEROSCLEROSIS, 1993, 104 (1-2) : 19 - 26
  • [9] The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications
    Boger, RH
    BodeBoger, SM
    Frolich, JC
    [J]. ATHEROSCLEROSIS, 1996, 127 (01) : 1 - 11
  • [10] PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE DEFICIENT MICE .2. EFFECTS ON HEMOSTASIS, THROMBOSIS, AND THROMBOLYSIS
    CARMELIET, P
    STASSEN, JM
    SCHOONJANS, L
    REAM, B
    VANDENOORD, JJ
    DEMOL, M
    MULLIGAN, RC
    COLLEN, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) : 2756 - 2760